Navigation Links
Ambit Biosciences Files Registration Statement for Proposed Initial Public Offering
Date:2/20/2013

SAN DIEGO, Feb. 20, 2013 /PRNewswire/ -- Ambit Biosciences Corporation today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) for an initial public offering of its common stock on the NASDAQ stock market. All shares of common stock to be sold in the offering will be offered by Ambit. The number of shares and price range for the offering have not been determined.

The joint book-running managers for the offering are Citigroup and Leerink Swann. In addition, BMO Capital Markets is acting as lead manager and Robert W. Baird & Co. Incorporated is acting as co-manager. The offering will be made only by means of a prospectus. When available, copies of the preliminary prospectus relating to and describing the terms of the offering may be obtained from Citigroup Global Markets Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York, 11717, or by email at batprospectusdept@citi.com or by phone at 1-800-831-9146, and Leerink Swann LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, Mass., 02110, or by email at Syndicate@Leerink.com or by phone at 1-800-808-7525.

A registration statement relating to these securities has been filed with the SEC, but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Ambit Biosciences

Ambit is a privately held biopharmaceutical company focused on the discovery, development and commercialization of drugs to treat unmet medical needs in oncology, autoimmune and inflammatory diseases by inhibiting kinases that are important drivers for those diseases. Ambit's lead drug candidate, quizartinib (AC220), is a once-daily, orally-administered potent and selective, inhibitor of FMS-like tyrosine kinase-3 (FLT3) and is currently under clinical development in patients with relapsed/refractory acute myeloid leukemia (AML) and in newly diagnosed AML patients in combination with chemotherapy as well as maintenance following a hematopoietic stem cell transplantation (HSCT). Ambit is developing quizartinib in collaboration with Astellas Pharma Inc. as part of a worldwide agreement to jointly develop and commercialize FLT3 kinase inhibitors in oncology and non-oncology indications. In addition to quizartinib, Ambit's clinical pipeline includes AC410, an oral JAK2 inhibitor, and CEP-32496, a BRAF inhibitor licensed to Teva Pharmaceutical Industries Ltd. Ambit's preclinical portfolio includes a proprietary CSF1R inhibitor program.

Contacts:
Alan Fuhrman (Investors)
Chief Financial Officer
(858) 334-2133

Ian Stone or David Schull (Media)
Russo Partners
(619) 308-6541
(212) 845-4271
ian.stone@russopartnersllc.com
david.schull@russopartnersllc.com


'/>"/>
SOURCE Ambit Biosciences Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. APAC Stem Cell Research & Therapy Market a “Growth Engine” for Region’s Scientific Ambitions Says A New Market Research Report at ReportsnReports.com
2. Astellas and Ambit Announce Data Presentations Highlighting Quizartinib at the American Society of Hematology 54th Annual Meeting
3. Ambit Biosciences to Present at Two Upcoming Investor Conferences
4. Ambit and Astellas Announce Results From Multiple Quizartinib Presentations at the 53rd Annual Meeting of the American Hematology Society
5. Ambit Biosciences Names Michael A. Martino President and Chief Executive Officer
6. Nano3D Biosciences Releases 96-well BioAssembler for 3D Cell Culture
7. Neurocrine Biosciences Reports Fourth Quarter And Year End 2012 Results
8. Sangamo BioSciences Announces Fourth Quarter And Full Year 2012 Conference Call And Webcast
9. IntelliCell BioSciences Announces the Addition of Harry Fisch, MD as Director of Urology
10. Avelas Biosciences Closes $7.65 Million Series A, Advances Real-Time Tumor Visualization Technology Toward Development
11. Pressure BioSciences, Inc. Appoints Conrad F. Mir as Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/21/2017)... -- Aratana Therapeutics, Inc. (NASDAQ: PETX ), ... and commercialization of innovative biopharmaceutical products for companion animals, ... North America 2016. ... the FDA approval of three innovative therapeutics in 2016, ... oral solution) and NOCITA ® (bupivacaine liposome injectable ...
(Date:1/20/2017)... http://www.Financialbuzz.com - According ... causes of death worldwide. There were 8.2 million cancer ... related deaths increased gradually over time, the death rates ... various cancers continues to drive demand of biological therapies ... Market Insights, Inc. cancer biological therapy market size was USD ...
(Date:1/19/2017)... 19, 2017 /PRNewswire -- WuXi AppTec, a leading ... and technology platform, today announced that it has ... preclinical drug discovery contract research organization (CRO). After ... wholly-owned subsidiary of WuXi, and will continue to ... greater services. The acquisition will further strengthen WuXi,s ...
(Date:1/19/2017)... , Jan. 19, 2017  ArmaGen, Inc., ... Schmidt , Ph.D., as chief executive officer, as ... directors. Dr. Schmidt brings to ArmaGen more than 17 ... research and development of biotherapeutics and pharmaceuticals. ... with the diverse experience and skillset necessary to ...
Breaking Biology Technology:
(Date:1/12/2017)... research undertaken by Fit Small Business has revealed ... simply asked which office technology had they not used in ... Insights on what will be key features in ... industry leaders including Penelope Trunk , Martin Lindstrom ... Some of these findings included; ...
(Date:1/6/2017)... JOLLA, Calif. , Jan. 6, 2017 /PRNewswire/ ... 1 safety studies in healthy volunteers of a ... intended to treat acute pancreatitis. ... is typically a mild disorder, but can be ... organ failure and sepsis, where extended hospital stays, ...
(Date:1/4/2017)... , Jan. 4, 2017  CES 2017 – ... sensor technology, today announced the launch of two ... systems, the highly-accurate biometric sensor modules that incorporate ... technology, experience and expertise. The two new designs ... specifically for hearables, and Benchmark BW2.0, a 2-LED ...
Breaking Biology News(10 mins):